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In vivo magnetic resonance imaging of glucose –
initial experience
Hyla Allouche-Arnona,b†, Trevor Wadec,d†, Lanette Friesen Waldnerc,d,
Valentina N. Millera, J. Moshe Gomoria,b*, Rachel Katz-Brulla,b{
and Charles A. McKenziec,d{
A new noninvasive, nonradioactive approach for glucose imaging using spin hyperpolarization technology and
stable isotope labeling is presented. A glucose analog labeled with 13C at all six positions increased the overall
hyperpolarized imaging signal; deuteration at all seven directly bonded proton positions prolonged the spin–lattice
relaxation time. High-bandwidth 13C imaging overcame the large glucose carbon chemical shift dispersion.
Hyperpolarized glucose images in the live rat showed time-dependent organ distribution patterns. At 8 s after
the start of bolus injection, the inferior vena cava was demonstrated at angiographic quality. Distribution of hyperpolarized glucose in the kidneys, vasculature, and heart was demonstrated at 12 and 20 s. The heart-to-vasculature
intensity ratio at 20 s suggests myocardial uptake. Cancer imaging, currently performed with 18 F-deoxyglucose
positron emission tomography (FDG-PET), warrants further investigation, and glucose imaging could be useful in
a vast range of clinical conditions and research ﬁelds where the radiation associated with the FDG-PET examination
limits its use. Copyright © 2012 John Wiley & Sons, Ltd.
Keywords: carbon-13; deuterium; hyperpolarization; uptake; 3 T; rat; DNP
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Glucose is probably the most researched biochemical since
fermentation was studied by Louis Pasteur (1) and glycolysis
was eventually delineated by Otto Meyerhof and colleagues
(2). Current glucose research includes studies of transporters
and metabolic enzymes at the molecular level, and translational
studies related to diabetes, inﬂammation and cancer (3).
In clinical imaging, the radioactive glucose analog 18 Fdeoxyglucose (FDG) is routinely used in positron emission tomography (PET) imaging procedures for identifying primary
and metastatic tumors. FDG-PET imaging is important in determining the extent of disease, and inﬂuences treatment decisions.
Recently, FDG-PET has been shown to have high sensitivity for
inﬂammation, speciﬁcally for identifying the origin of fever of
unknown origin (4). However, radiation exposure associated
with FDG-PET studies limits repeat examinations, precludes
imaging of children and pregnant women except in unusual
circumstances, and prevents the use of this valuable imaging
technique in humans for wide-ranging research relating to brain
function in health and disease and to glucose utilization in bodily
organs in situ.
Nonradioactive analogs of glucose, labeled with the stable
isotope carbon-13, have been used in the last three decades to
study glucose metabolism in tissue culture, small animals and
humans with the aid of the noninvasive technology of magnetic
resonance spectroscopy (MRS) (5–11). Glucose analogs and
derivatives labeled with both carbon-13 and deuterium have
also been used to monitor glucose metabolism ex vivo. For
example, [1-13C]glucose and [6,6-2H2]glucose were utilized as a
means to monitor human glucose metabolism (12). The metabolic products of these labeled glucose analogs were assayed
in body ﬂuids by means of gas chromatography combined with
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mass spectrometry. In another study [1,6-13C2]glucose with or
without deuterium labeling (D16) was used to monitor glucose
metabolism in humans by NMR spectroscopy of blood and urine
samples (13). Glucose analogs labeled with stable isotopes have
also been used to study glucose metabolism noninvasively in
animals and humans (14).
Recent advances in spin hyperpolarization (15–17) raised
hopes for noninvasive and nonradioactive glucose imaging and
monitoring of metabolism using MRI. However, it was found that
the T1 of glucose carbons is <2 s which is prohibitively short for
hyperpolarized MRI applications (18). Capitalizing on our experience with new molecular imaging agents for the hyperpolarized
MR technology using deuteration of sp3 carbon-13 positions
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HYPERPOLARIZED MRI OF GLUCOSE IN VIVO
(19,20), we show here that direct glucose imaging is feasible
in vivo, by MRI, using a glucose analog that is labeled with stable,
nonradioactive isotopes. This analog, [U-13C6, 2 H7]glucose, is
enriched with carbon-13 in all carbon positions and enriched
with deuterium atoms in all proton positions that are directly
bonded to carbons. We show that this strategy allows nonradioactive, noninvasive imaging of glucose with an off-the-shelf
compound.

2. RESULTS
To capitalize on the DNP spin polarization technology for
glucose imaging, the T1s of the glucose carbons must be long
enough to provide a sufﬁcient temporal window for observing
the hyperpolarized state in a living subject. The T1 of the glucose
carbon-13 nuclei was previously reported to be <2 s for all
carbon positions, making glucose unsuitable for use with the
DNP technique (18). Our studies conﬁrmed this ﬁnding, showing
an average T1 for native glucose carbons of 1.6  0.4 s (mean
standard deviation) for a 400 mM solution in water at 11.8 T
and 37  C. To further study the suitability of glucose for the
DNP technique, we investigated the effects of sp3 carbon
deuteration (19), that is, substitution of directly bonded hydrogen(s) by deuterium atoms for a tetrahedrally coordinated
carbon, on the T1 of these carbons. Deuteration was found
to prolong the T1 of these sp3 carbons but other factors such
as concentration, magnetic ﬁeld and directly bonded- or adjacent carbon-13 nuclei were found to inﬂuence this relaxation
time as well, as described below. We have investigated the
possible effects of these factors in order to guide utilization
of glucose’s sp3 carbon deuteration in various potential hyperpolarized glucose MR applications including imaging and
spectroscopy.
2.1.

Concentration and Osmolarity
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was found to be longer at the lower dilution (Table 1 and Fig. 1).
The mean difference between the T1 values at 400 and 40 mM
was 6.5  1.8 s (8.9  1.5 s at 400 mM vs 15.4  1.8 s at 40 mM, a
74% increase). However, when the osmolarity of the 40 mM
solution was raised to 400 mOsm (by addition of sodium
chloride), the T1 of glucose carbons decreased to 12.5  1.3 s
(41% decrease) yet remained above that of glucose carbons in
the 400 mM glucose solution (Table 1 and Fig. 1). Further investigation into the effect of concentration and solutes on the T1 of
[U-13C6, 2 H7]glucose carbons is underway.

2.2.

Magnetic Field Strength

The effect of magnetic ﬁeld strength on the T1 of [U-13C6, 2 H7]
glucose carbons was investigated at 7, 11.8 and 4.7 T under
thermal equilibrium conditions (400 mM in water, 37  C), as well
as at 3 T, in a hyperpolarized state. The T1 of [U-13C6, 2 H7]glucose
carbons was longer at 7 T compared with 11.8 T (Fig. 1 and
Table 1), with a mean difference of 2.4 1.6 s between both
ﬁelds (11.2  1.6 vs 8.9  1.5 s).
Figure 2 shows the structure of the [U-13C6, 2 H7]-D-glucose a and
b anomers and the various carbon positions and deuteration sites
therein. The 13C spectrum of this molecule at 11.8 T is shown with
assignment for the eight main groups of signals observed. At 7 T,
these eight groups of signals are resolved as well. However, at
4.7 T the ﬁve signal groups between 70 and 80 ppm overlap. Nevertheless, positions 1 and 6 could be resolved and showed T1 values of
8.3 and 6.2 s, respectively (Table 1).

Copyright © 2012 John Wiley & Sons, Ltd.

wileyonlinelibrary.com/journal/cmmi

73

The effect of high [U-13C6, 2 H7]glucose concentration on the T1
of glucose carbon positions was ﬁrst investigated at 7 and
11.8 T (Fig. 1 and Table 1) under thermal equilibrium conditions.
The T1 of glucose carbons was found to be longer in a 400 mM
solution compared with a 10-fold concentrated solution (4.03 M)
at both magnetic ﬁelds. The mean difference between the T1
values for the two concentrations was 6.9  1.4 s (4.0  0.5 vs
10.9  1.7 s, a 174% increase) and 4.5  1.4 s (4.4  0.4 vs
8.9  1.5 s, a 103% increase) at 7 and 11.8 T, respectively. The
mean T1s and standard deviations were calculated from the data
obtained for eight groups of signals as shown in Fig. 2 and
summarized in Table 1.
High osmolality media are typically in the range of 5–8 times
the osmolality of plasma (21), that is, not above ca. 2.4 M. Therefore, the 4.03 M solution is too concentrated to serve as a contrast
medium. However, the 400 mM solution can be considered to be
in the range of iso-osmolar to low-osmolality contrast medium,
whereas such low-osmolality media typically have up to 2–3
times the osmolality of plasma (21), that is, 600–900 mM. The
above ﬁndings therefore suggested that iso- to low-osmolality
conditions are favorable for T1 prolongation, and that hyperpolarized glucose media should not be kept at high osmolarity
during transfer of hyperpolarized glucose from the polarizer to
the subject and administration to the subject.
The effect of concentration was further investigated in a
solution of 40 mM [U-13C6, 2 H7]glucose in water at 11.8 T. The T1

Figure 1. T1 of 13C nuclei in deuterated glucose molecules. The labels
Cia and Cib mark the signals of the glucose carbon at position i in the a
and b anomers, respectively. The studies were carried out at 37  C. All
solutions were made in puriﬁed water containing 10% D2O. The error
bars represent the 95% conﬁdence interval as determined by the
inversion-recovery curve ﬁtting. The exact values for each position are
given in detail in Table 1 and in the text. These varied conditions provide
means to assess the effect of concentration, osmolarity, magnetic
ﬁeld strength and 13C–13C dipolar interactions on the T1 of the various
13
C nuclei.
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11.6 (9.6, 13.6)

10.2 (9.0, 11.3)

8.3 (6.0, 10.5)

5.8 (4.2, 7.4)

4.5 (4.3, 4.6)

(C2+ C5)a
3.6 (3.2, 4.0)

9.0 (7.6, 10.4)

4.3 (4.2, 4.4)

C3 a
3.9 (4.8, 4.0)

10.1 (8.7, 11.5)

4.7 (4.6, 4.7)

(C3+ C5)b
4.9 (4.8, 5.1)

8.2 (7.0, 9.4 )

8.4 (7.9, 8.9)

9.5 ( 0.6)b

7.0 (3.1, 10.8)

8.0 (5.2, 10.8)

b

6.2 (6.0 ,6.4 )

16.6 (14.8, 18.4) 16.9 (16.4, 17.5) 15.9 (15.3. 16.4) 16.1 (14.4, 17.8) 16.0 (13.0, 19.0) 14.3 (14.0, 14.5) 16.2 (15.7, 16.7) 11.4 (11.0, 11.7)

9.7 (8.7, 10.7)

13.4 (12.2, 14.7) 13.5 (12.5, 14.5) 13.6 (12.3, 14.9) 12.7 (11.9, 13.4) 12.5 (11.5, 13.4) 11.9 (11.5, 12.3) 12.9 (12.4, 13.3)

9.1 (8.0, 10.2)

7.4 (6.4, 8.5)

3.5 (3.5, 3.5)

C6(a + b)
3.2 (3.0, 3.5)

9.3 (7.6, 11.0)

12.7 (12.3, 13.0) 13.2 (11.8, 14.7)

9.3 (8.1, 10.4)

4.2 (4.1, 4.3)

C4(a + b)
3.7 (3.6, 3.9)

12.0 (10.3, 13.7) 12.6 (11.7, 13.5)

11.3 (9.1, 13.5)

11.1 (10.3, 12.0) 11.4 (8.5, 14.2)

9.6 (8.5, 10.8)

4.7 (4.5, 4.9)

C2 b
4.4 (4.1, 4.6)

T1 at position and anomer (s)a

12.7 (10.1, 15.2) 12.9 (10.0, 15.8) 13.5 (11.9, 15.0) 13.3 (9.9, 16.7)

9.9 (8.6, 11.3)

4.5 (4.3, 4.6)

C1 b
4.1 (3.9, 4.2)

9.8 (8.6, 11.1)

4.6 (4.5, 4.7)

C1 a
4.1 (3.9, 4.3)

C nuclei in deuterated glucose

Molecule and conditions
[U-13C6, 2 H7]glucose, 7 T,
4.03 M, 4.03 Osm, TE
[U-13C6, 2 H7]glucose, 11.8 T,
4.03 M, 4.03 Osm, TE
[U-13C6, 2 H7]glucose, 11.8 T,
400 mM, 400 mOsm, TE
[U-13C6, 2 H7]glucose, 7 T,
400 mM, 400 mOsm, TE
[2 H7]glucose, 11.8 T,
400 mM, 400 mOsm, TE
[U-13C6, 2 H7]glucose, 11.8 T,
40 mM, 400 mOsm, TE
[U-13C6, 2 H7]glucose, 11.8 T,
40 mM, 40 mOsm, TE
[U-13C6, 2 H7]glucose, 4.7 T,
400 mM, 400 mOsm, TE
[U-13C6, 2 H7]glucose, 3 T,
26 mM, 314 mOsm, HP

13

95% Conﬁdence interval provided by the curve ﬁtting is shown in brackets.
Mean and standard deviation of three studies as reported in the Experimental section.
TE, Data acquired under thermal equilibrium conditions (see Experimental section). HP, Data acquired at a hyperpolarized state (see Experimental section).

a

I

H

G

F

E

D

C

B

A

Table 1. T1 of
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Extrapolating back to the point of dissolution at the DNP
polarizer, taking into account 15  2 s as the duration between
the end of polarization and the measurement in the scanner,
the polarization would be 21  6% in solution at the DNP
polarizer immediately after dissolution. It is not possible to
account for the effect on the ﬁnal polarization of variations
in magnetic ﬁeld during transport of the agent from polarizer
to MRI scanner; therefore, this represents a lower bound on
the error.
2.4.

Figure 2. 13C spectrum of [U-13C6, 2H7]glucose in water at 11.8 T and
37  C. Eight groups of signals were assigned to their corresponding carbon
positions in the molecule. The structure of the a and b anomers of
[U-13C6, 2H7]-D-glucose is shown at the top. D, Deuterium atoms; * 13C
atoms. The various carbon positions (Ci) are marked by numerals. Heteronuclear irradiation (proton or deuterium) was not applied.

The T1 of [U-13C6, 2 H7]glucose at 3 T was found to be
9.5  0.6 s (n = 3). In this measurement, the integrated intensity
over all of the carbon positions was used owing to the difﬁculty
in resolving the various carbon signal groups in the 3 T spectra.
Three hyperpolarized studies were performed in solution, as
described in the Experimental section.
Altogether, although [U-13C6, 2 H7]glucose T1s were found to
vary at different magnetic ﬁelds, we could not identify a clear
trend for this variation. Because the ability to resolve the
individual [U-13C6, 2 H7]glucose carbons’ signals decreases with
a decrease in the magnetic ﬁeld strength, a detailed analysis of
the T1 dependence on magnetic ﬁeld for each carbon position
is not possible with the fully 13C labeled molecule as the signals
of the different positions heavily overlap. For this reason the T1 at
3 T was calculated as an average for the six carbon positions in
the a and b anomers together.
2.3.

Polarization

Contrast Media Mol. Imaging 2013, 8 72–82

To gain maximal signal from hyperpolarized glucose we chose to
use a glucose analog that is labeled in all carbon positions. The
possible effect of direct carbon-13 to carbon-13 bonding on
the individual carbon-13 T1s was investigated to study the effect
of these added dipolar interactions on T1 relaxation times. To this
end, two compounds were investigated: [U-13C6, 2 H7]glucose
and [2 H7]glucose at 400 mM, 37  C and 11.8 T (Fig. 1 and Table 1).
While both compounds are fully deuterated, all carbon positions
in the [U-13C6, 2 H7]glucose molecule are 99% occupied by 13C
nuclei, while only ca. 1.1% of each carbon position is occupied
by 13C nuclei in the [2 H7]glucose molecule owing to the naturally
abundant distribution of 13C. The chance of having two directly
bonded 13C nuclei in the latter molecule is therefore 0.01%
(negligible); thus this measurement was indicative of the T1 of
a single 13C-labeled glucose. It was found that the T1 of glucose
13
Cs in a uniformly 13C-labeled glucose was shorter by 3.3 s
(8.9  1.4 s vs 12.2  1.3 s, 27% decrease). Therefore, direct
bonding of additional 13C nuclei led to a decrease in glucose
13
C T1s, as could be expected owing to the additional dipolar
interactions. However, as can be seen in the following, this
decrease in T1 did not prevent imaging of hyperpolarized
[U-13C6, 2 H7]glucose.
The fully deuterated and fully 13C labeled [U-13C6, 2 H7]glucose
has two competing properties in terms of its potential hyperpolarized signal. On one hand, it is labeled at six positions, all with
similar T1. This property can be utilized to increase the initial
hyperpolarized signal 6-fold. On the other hand, the T1s of these
carbon-13 nuclei are shorter than any hyperpolarized probe
reported to date (17).
2.5.

Simulation of Signal Enhancement and Decay

To gain insight into the relative imaging signal increase that
would be provided using this glucose analog in a hyperpolarized
state, we simulated its signal enhancement and decay,
comparing the signal expected from the glucose analog to that
of [1-13C]pyruvate (Fig. 3). The latter agent and acquisition
approach are considered a ‘gold standard’ in the ﬁeld, with known
enhancement characteristics (17). In the simulation we considered
that: (a) pyruvate is injected at a dose of 0.2 mmol kg1,
as previously described (16), and glucose is injected at a dose of
1.4 mmol kg1, which is approximately half the dose that is safe
for injection in humans, as per the intravenous glucose tolerance
test (see Discussion); (b) the initial liquid state polarizations per
13
C nucleus (immediately following dissolution) are the same; (c)
the T1 of pyruvate is 55 s (16); (d) the T1 of glucose is positionand anomer-dependent; and (e) the bandwidth for image
acquisition is the same.
Individual position T1 values (T1_ci), as determined at 7 T, 400 mM
and 37  C, were used in this calculation (8–13 s), assuming that the

Copyright © 2012 John Wiley & Sons, Ltd.
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The polarization level of [U-13C6, 2 H7]glucose in the solution in
the magnet was 4.2  0.4% (n = 3). We note that the glucose
polarization protocol was not optimized and was based on a previously developed polarization protocol for choline analogs (20).
It may be that optimization would lead to a higher polarization
level. In addition, the transfer time from the polarizer to the
magnet (15  2 s) was long compared with the T1 of the
compound (9.5 s at 3 T). Therefore, shortening the transfer time
is likely to have a substantial effect on the measured polarization
level as well.

Carbon-13 Dipolar Interactions

H. ALLOUCHE-ARNON ET AL.
2.6.

Figure 3. Simulation for the relative imaging signal of hyperpolarized
[U-13C6, 2H7]glucose compared with hyperpolarized [1-13C]pyruvate. The
underlying assumptions for this simulation are described in the text.
Individual [U-13C6, 2H7]glucose carbon T1 values, as determined at 7 T,
400 mM and 37  C, were used in this simulation (see Table 1 and Fig. 1).
The lower panel is an expanded version of the upper panel.
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a to b anomer ratio is 36:64 (22). The overall glucose signal at a particular time point was calculated as ΣSci, where Sci is the individual
signal for each carbon position at a particular time point. Each Sci
was calculated according to Sci(t) = ISNR  exp(t/T1_ci), where ISNR
is the initial signal-to-noise ratio (SNR) or the initial relative
imaging signal. The glucose decay curve was normalized to that
of pyruvate using the dose ratio, that is, the ISNR of each glucose
carbon was taken to be 7-fold that of pyruvate, whereas the latter
was set to 1 arbitrary unit.
Considering a duration of approximately 30 s from dissolution
start for transfer and injection, this simulation suggests a temporal window for imaging of approximately 25 s, during which the
expected signal of hyperpolarized [U-13C6, 2 H7]glucose is higher
than that of hyperpolarized [1-13C]pyruvate (Fig. 3). The simulation also suggests that a remarkable increase in signal may be
gained by minimizing the transfer and/or the injection duration.
We note that an imaging signal is always greater than a spectroscopic signal because it integrates over all of the intensities of
the injected agent as well as its metabolites. Nevertheless this
factor was not taken into account in the simulation because
the differences between the total hyperpolarized signal and an
individual hyperpolarized metabolite signal are time-dependent
and speciﬁc to the tissue under investigation, both for glucose
and for pyruvate. Therefore, one cannot assign a constant factor
for this expected signal increase, although this property is
expected to prolong the imaging time window shown in Fig. 3.

wileyonlinelibrary.com/journal/cmmi

Hyperpolarized Glucose Imaging – in vitro

Encouraged by these simulation results, the ﬁrst hyperpolarized
glucose image was recorded at 3 T. A syringe ﬁlled with approximately 2.5 ml of hyperpolarized [U-13C6, 2 H7]glucose solution
(104 mM) was placed at the center of the RF coil and the image
was recorded within approximately 15–20 s after dissolution
(Fig. 4a). Indeed, as expected, the image showed ample signal
and very low noise. However, owing to the dispersion of glucose
carbons’ chemical shifts, several carbon lines are visible. Because
the chemical shift dispersion in the glucose spectrum is about
35 ppm (~1120 Hz), the read bandwidth of 3 kHz is of the order
of the chemical shift dispersion, leading to substantial chemical
shift artifact. The distance between the most extreme lines in
Fig. 4(a) is about 4.5 cm. This is a remarkable presentation of a
chemical shift artifact, usually visible on anatomic 1 H MRI images
in regions with both fat and water. To correct for this artifact, a
second image was recorded with a high bandwidth (42 kHz).
Using these conditions, the individual carbon signals collapsed
to yield an artifact-free image with high in-plane resolution and
high SNR, despite the loss in SNR at higher bandwidth. This
SNR loss was at least partially compensated for by collapsing
all the spectral peaks into a single voxel, as seen in Fig. 4(b). In
order to calculate the effect of high-bandwidth acquisition
on scaling of the total signal in the glucose image, the signalto-noise in the two images was compared as described in
Table 2. The SNR in the low bandwidth image was 5.4  105.
Because the signal is expected to remain the same and the noise
is expected to scale as the square root of the bandwidth, the
expected signal-to-noise ratio in the high bandwidth image is
1.4  105. The experimental SNR at the high bandwidth image
was found to be 1.6  105, slightly higher but in agreement with
expectations.

Figure 4. Carbon-13 MRI images of a syringe ﬁlled with hyperpolarized
[U-13C6, 2 H7]glucose. Image (a) was recorded with a 3 kHz bandwidth
and demonstrated chemical shift dispersion between the glucose
carbons. Image (b) was recorded with a high bandwidth (42 kHz) to
minimize the chemical shift artifact by collapsing all the carbon chemical
shifts to approximately one pixel.

Copyright © 2012 John Wiley & Sons, Ltd.
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Table 2. Signal-to-noise characteristics of hyperpolarized
glucose at low and high bandwidth imaging

Total signal (a.u.)a
Mean signal (a.u.)b
Real noise (a.u.)c
Signal-to-noise ratio
Band-width (kHz)

Low bandwidth
image

High bandwidth
image

3.8  105
133
0.7
(5.4  0.1)  105
3.01

7.2  105
1075
4.5
(1.6  0.1)  105
41.67

a.u., Arbitrary units.
a
Total signal is based on the sum of the signal in a region of
interest consisting of all visible intensities in the images.
b
Mean signal represents the mean of the intensities in the
same regions of interest.
c
Noise was based on the standard deviation of the real signal
in reference noise scans (no RF).
2.7.

Hyperpolarized Glucose Imaging – in vivo

As depicted in Fig. 5, hyperpolarized [U-13C6, 2 H7]glucose also
provided a high signal on carbon-13 images recorded in vivo.
Normal rats were anesthetized, and hyperpolarized [U-13C6,
2
H7]glucose was injected through the tail vein in a bolus of
12 s total duration. Projection images were recorded at 8, 12
and 20 s from the onset of the bolus injection (i.e. during and
after the bolus). Each image was acquired within 1 s; three
different animals are shown. Cardiac gating was not applied;
therefore, each image averages several heart beats.
In the image recorded at 8 s (Fig. 5a), the inferior vena cava and
the heart are clearly visible. Arterial hyperpolarized media ﬂow at
this time is not likely, as the signal in the kidneys is not yet visible.
This image, which was recorded during the bolus at a very high
resolution (128  128 matrix, in-plane resolution of 1.56 mm),
demonstrates the potential of hyperpolarized glucose imaging
with regard to angiography. The signal from the injected hyperpolarized media is extremely high with no background signal.

At 12 s (Fig. 5b), at the end of the bolus injection, signal
intensity in the main vasculature and the heart is high, with
substantial intensity observed in the kidneys. At 20 s from bolus
initiation (Fig. 5c), signal from the heart is the most intense signal
in the image, about 40% higher than the signal in the vasculature and about 20% higher than the signal in the kidneys. Still,
the signal in the kidneys is clearly observed, as well as the signal
in other tissues such as the liver.

3.

DISCUSSION

The ﬁrst nonradioactive images of glucose distribution in live rats
are presented. Several aspects regarding the current results and
suggested applications are discussed below.
3.1.

The use of DNP for Imaging of Hyperpolarized Media

DNP hyperpolarization technology has offered the possibility of
a new imaging modality ever since it was ﬁrst described in vivo
in 2004 (16,23). The main emphasis of this technology thus far
has been visualization of actual metabolic conversions in vivo
(17), with the exception of the very ﬁrst in vivo paper, which used
a nonmetabolic compound (23). This property of metabolic visualization is indeed unmatched by any other imaging modality
available today. However, we felt that the ample signal provided
by hyperpolarization may be advantageous per se for monitoring
the distribution of metabolically important compounds, even
without obtaining information on speciﬁc metabolic pathways.
Of speciﬁc interest are compounds with uptake characteristics
that are favorable for identifying pathologies. FDG-PET has
already revealed the promise of glucose uptake as a biomarker.
For this reason, we have attempted to image glucose with
hyperpolarized MRI. Technically, the use of 13C imaging as
opposed to spectroscopic imaging, which is usually performed
for metabolic analysis, provides a relative increase in SNR
(owing to the combined signal of all metabolites) and lowers
the demands of nonroutine pulse sequence and reconstruction
tools.
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Figure 5. Carbon-13 MRI images of rats injected with hyperpolarized [U-13C6, 2 H7]glucose. Images were recorded: (a) during the injection – 8 s from
injection start; (b) at the end of the injection – 12 s from injection start; and (c) after the injection – 20 s from injection start, in three different rats. Color
hyperpolarized images are presented overlaid on proton images from the same rat. The color scales represent arbitrary linearly distributed intensity
units for the hyperpolarized images. Each image is presented with the optimal viewing window and the relative intensities in the three images can
be compared based on the corresponding color scale. The hyperpolarized signals in the kidneys and the inferior vena cava are marked with white
and orange arrows, respectively. The green arrow points to the hyperpolarized signal in the heart and lungs in (a) and (b) and apparently only the heart
in (c). The regions of the head and tail of the rats were outside the ﬁeld of view of both RF coils – 1 H and 13C.
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3.2.

SNR – Fully

13

C-Labeled Glucose
13

While the use of fully C-labeled glucose has 6-fold SNR per
mole compared with a singly 13C labeled molecule, we note that
the wide range of chemical shifts dictated a high bandwidth for
imaging of 42 kHz, thus reducing some of the beneﬁt of the
increased SNR. It is possible that imaging singly labeled glucose
with smaller bandwidth may provide SNR similar to that reported
here, but this depends very strongly on the particular conditions
of the experiment, including the T1 values of the particular
carbon position selected for labeling (currently unknown at 3 T)
and the frequency spread of the 13C signal of that position when
metabolized.
3.3. Glucose for DNP – Molecular Agent Life Time and
Imaging Time
The ability of a compound to serve as a molecular imaging agent
on hyperpolarized MRI is dependent to a great extent on the T1
of its relevant 13C nucleus or nuclei. We found that substituting
directly bonded protons with deuterium atoms led to a signiﬁcant T1 prolongation and enabled glucose monitoring in a hyperpolarized state.
The lifetimes demonstrated here for hyperpolarized [U-13C6, 2 H7]
glucose at 3 T were of the order of ~29 s (ca. 3 times the average
T1), which is extremely short compared with the half life of FDG
(2 h). Also, the temporal window at which the FDG-PET image is
recorded is within 30–60 min from FDG administration. However, a
shorter half-life of ca. 2 min was recently reported for an oxygen15 deoxy-glucose analog, [15O]DG (24). Using this relatively shortlived analog, it was possible with PET imaging to show tissue
contrast with regions of high glucose uptake or accumulation such
as the brain, heart, kidneys and bladder at high intensity, a contrast
pattern that is similar to that of [18 F]FDG-PET. This pattern was
evident already at 5 min post [15O]DG administration. Importantly,
H15
2 O administration in the same study showed no speciﬁc contrast
and a uniform distribution of the label in the body. This study is
encouraging in terms of the feasibility of monitoring tissue glucose
uptake with a short-lived imaging agent.
3.4.

Glucose Uptake and Metabolism
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The entire glycolysis pathway, starting from glucose transport
and downstream metabolism to CO2 or ethanol, was recently
demonstrated in vivo – in yeast – in less than 20 s using the same
glucose analog as used here: [U-2 H, U-13C] (25). We believe that
such a study, which used the same noninvasive technology, that
is, NMR spectroscopy, and the same glucose analog, is the most
relevant for discussing the rates of glucose metabolism with
respect to the time frame of the current experiments.
Transport across the plasma membrane is the ﬁrst, obligatory
step of glucose utilization. Facilitated diffusion-type glucose
transport in yeast occurs via the hexose family of transporters,
which is composed of at least 20 known genes coding for
transport of glucose with a Km ranging between 1.5 and
100 mM (26). Glucose transport of a facilitated diffusion type in
mammalians occurs via the GLUT/SLC2 family of transporters,
which is composed of 13 known members. The distribution of
the GLUT family members is tissue speciﬁc and depends on
physiological conditions. The Km of GLUT1 and GLUT3 is approximately 1 mM (high afﬁnity) while GLUT 2 has a lower afﬁnity of
approximately 15–20 mM. Therefore, similar high-afﬁnity facilitated diffusion glucose transporters are found in yeast as well as
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in mammals. In the experiments described herein (in mammals),
glucose concentration in the blood is high and therefore the facilitated diffusion carriers are likely to be the dominant transport
system, as opposed to secondary active glucose co-transport.
Assuming that the rate of in vivo facilitated diffusion glucose
transport is the same in yeast and mammals, we would expect
glucose metabolism to occur in mammals at a similar rate to that
found in yeast. Therefore, within the experimental time frame of
20 s described herein we would expect glucose metabolism
to occur in mammals in general and speciﬁcally in the rats
that were studied here. We note that glucose metabolites may
differ from glucose in their relaxation properties. As we do not
know the composition of glucose metabolites in tissue, we cannot
speculate on their overall T1 relaxation behavior. Nevertheless,
we note that the end metabolites of glycolysis in mammals, CO2
and lactate are both compounds with a longer T1 than glucose.
Therefore, decay of the signal owing to metabolism in the tissue
is not likely.
Nevertheless, we note that monitoring metabolism was not
the purpose of the current study. The most probable tissue in
which metabolism would occur would be the heart muscle,
which is the only tissue in the anesthetized rat that is expected
to show high GLUT1 activity because under anesthesia it is the
only active muscle. The brain, which very actively takes up
glucose in conscious subjects, as seen on clinical FDG-PET
images, actually has very low glucose metabolism under
anesthesia, and was therefore not imaged in the present study.
Although hyperpolarized spectroscopy had been previously
recorded from the heart using hyperpolarized pyruvate (27),
we note that such a study requires an experimental protocol that
is not straightforward, including: larger animals, dedicated pulse
sequences and cardiac gating. Further studies are needed to
monitor possible hyperpolarized glucose metabolism in the
myocardium or in other tissues.
Although we did not monitor metabolism, the intense hyperpolarized glucose signal observed in the heart at 20 s from bolus
start (Fig. 5c) was suggestive of glucose uptake because it was
more intense than the signal in the vasculature and the kidneys.
We note that heart anatomy cannot be discerned from these
hyperpolarized images because the imaging time (1 s) averaged
several heart beats (approximately six beats) and cardiac gating
was not applied. In addition, signal from hyperpolarized glucose
in the blood within the heart could be contributing to this effect.
Further studies using MRI techniques that eliminate signal from
the blood pool are underway in our team to investigate the
possibility that glucose uptake by the myocardium can indeed
be determined at short time frames of the order of 20 s.
3.5.

Hyperpolarized Glucose MRA

In Fig. 5(a), we show a glucose image obtained as the bolus of
hyperpolarized media advances through the inferior vena cava.
This image illustrates the usefulness of this imaging approach
in catheter angiography. In this application, glucose is used as
a safe, high-intensity, injectable agent. At the time this image
was recorded, the solution used (53 mg per 4 ml or 68.6 mM) is
likely to be diluted by the rat’s blood and represents a concentration of <68.6 mM. In the intravenous glucose tolerance test, a
bolus of glucose as 300 mg kg1 in a 30% solution (1.67 M), a very
high osmolarity medium, is given within 60 s (28). Considering
this range of injectable glucose concentrations (68.6–1670 mM)
we discuss in the following the signal strength and expected
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image contrast that may be obtained clinically. Because MRI
resolution is limited by the amount of polarized nuclei per
voxel, the possible polarizations of glucose and water are compared. We choose the case in which glucose is injected in an
iso-osmotic medium of 300 mM (which equals 300 mOsm).
If hyperpolarized isotopically labeled glucose is injected via a
catheter as a solution of ca. 300 mM, the glucose concentration
in blood in the immediate proximity of the injection site would
be close to 300 mM. We assume a polarization enhancement
factor of about 1000 for each of the six carbon-13 nuclei. Such
an enhancement at a ﬁeld of 3 T is expected to lead to a signal
level in the vasculature of 1980 M ppm, (0.3 M, thermal polarization for 13C of about 1.1 ppm, an enhancement factor of 1000,
and six carbons per molecule). In comparison, the signal level
of Gd-enhanced angiography is limited by the amount of polarized water protons (regardless of the amount of Gd-chelate). This
polarization at 3 T is about 500 M ppm, (55.5 M, the concentration
of water in water is taken as an upper limit for the concentration
of water in blood, thermal polarization for 1 H of 4.5 ppm, and
two protons per molecule). Considering a 4-fold lower SNR for
13
C compared with 1 H MRI owing to its lower gyromagnetic
ratio, the expected hyperpolarized glucose signal is therefore
similar to that of thermal equilibrium proton imaging. However,
while in Gd-enhanced proton-MR angiography (MRA) the
nonenhanced tissue provides a considerable background signal,
the lack of background signal in the hyperpolarized application
is likely to produce angiographic images with higher contrastto-noise ratio. In addition, the possibility of injecting hyperosmotic glucose solutions and the potential to reach polarization
enhancement factors greater than 1000 may both lead to higher
SNR in the hyperpolarized images compared with thermal
equilibrium proton imaging.
Glucose MRA could therefore present an alternative to
gadolinium contrast-based MRA, particularly for patients at risk
of nephrogenic systemic ﬁbrosis, including those with compromised kidney function (29). Glucose MRA could also be an
attractive alternative to X-ray or CT angiography, which are
associated with high radiation doses for patients, technicians
and physicians. We note that the resolution of CT catheter
angiography is high, about 0.2–0.25 mm in plane resolution. It
remains to be seen whether the added signal owing to high
concentration of hyperpolarized [U-13C6, 2 H7]glucose as a contrast agent could lead to such high resolution in catheter MRA.
Indeed, other compounds such as [13C]urea have been previously suggested as DNP hyperpolarized agents beneﬁcial for
angiography (15). Urea has low toxicity for intravenous administration and a similar water solubility to glucose. This makes urea
a good candidate for catheter angiography. However, while urea
has only one carbon position, glucose has six positions, which
offer a 6-fold signal enhancement for very short observation
times (assuming their initial polarization level is the same). For
immediate observation after release of the contrast medium as
requested in catheter angiography, [U-13C6, 2 H7]glucose appears
to be advantageous.
3.6.

Safety Proﬁle
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3.7.

Technological Perspective

Generally, pending proof of efﬁcacy, MRI is an attractive alternative to PET for operational and safety reasons. Using MRI and
hyperpolarized glucose analogs may provide alternatives to
FDG-PET examination. This new route for glucose imaging could
reduce the need for hybrid imaging systems such as PET-CT and
PET-MRI because the entire anatomical imaging and functional/
uptake/distribution examination can be performed in a conventional MRI scanner equipped with 13C compatible hardware; thus
glucose MRI could reduce the cost of such medical imaging
applications, if it demonstrates comparable information.
3.8.

Clinical Perspective

Tissue uptake of glucose has not been unequivocally demonstrated here. Currently, FDG-PET is mostly focused on oncologic
applications, for the identiﬁcation of primary and metastatic
tumors. It remains to be seen whether this new glucose imaging
approach could identify primary and metastatic tumors with the
same level of conﬁdence as FDG-PET. Nevertheless, in the
current study two new applications – glucose MRA and cardiac
glucose uptake – have been suggested. We believe that the
hyperpolarized MRI approach will open the door to a wide range
of glucose imaging studies. These may include studies on infection and inﬂammation, neurologic and psychiatric conditions,
epilepsy, cardiovascular applications, kidney function and numerous other topics currently unforeseen.
3.9.

Glucose, Deoxyglucose and other Glucose Derivatives

2-Deoxy-2-ﬂuoro-D-glucose (FDG) at natural abundance, without
stable isotope or radioactive labeling, has been used to study
deoxy-glucose metabolism by 19 F-NMR. The main metabolites
found were FDG-6 phosphate (FDG-6-P), its epimer 2-deoxy-2
ﬂuoro-D-mannose-6 phosphate (FDM-6-P), and their nucleosidedi-phosphate (NDP) forms, NDP-FDG and NDP-FDM (30). The
limited cellular metabolism of FDG accounts for its inability to
leave the cell, which is the basis for determining tissue uptake
using FDG. Considering future applications of the approach
demonstrated here, it could be advantageous to monitor a
glucose derivative that has the same limited metabolic proﬁle
using hyperpolarized MRI. Such a derivative would be 2-deoxy13
D-glucose that is fully labeled with C and labeled with deuterium
at all directly bonded proton positions, namely [U-13C6,D8]-2deoxy-D-glucose (2DG).
In this respect, we note that the acute toxicity of intravenously
injected 2DG was previously investigated in rats: no death was
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When developing molecular imaging agents or contrast agents
for clinical use, safety is an issue of utmost importance. In potential clinical applications that are suggested by the current studies
in rats, glucose appears to have a uniquely promising safety proﬁle. In clinical practice, the intravenous glucose tolerance test is

widely used in the detection of diabetes and insulin resistance,
and for investigation of early insulin secretion abnormalities in
prediabetic states. It may also be used to test for reactive
hypoglycemia and other disorders of carbohydrate metabolism.
In such intravenous glucose tolerance tests, a glucose dose of
0.5 g kg1 body weight is administered intravenously in a bolus
injection. This dose is safe, and places glucose as one of the safest agents that can be administered intravenously to human
subjects. Only about one-quarter of this dose was used in the
current study, and human studies may require an even lower
dose owing to the generally more active state of the conscious
subject compared with the anesthetized rat; however, there is
clearly considerable room to increase the dose should additional
SNR be required.
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reported, and there was no change in heart rate or respiratory
rate at doses of 0.25, 0.5 or 1 g kg1. There was a mean decrease
in arterial blood pressure at such high doses, but not in a
dose-dependent manner (31).
The tissue contrast obtained clinically with radioactive
deoxy-glucose in PET images reﬂects increased deoxy-glucose
uptake owing to higher glucose transporter expression, especially GLUT1. Several glucose derivatives, such as deoxy-glucose
and glucosamine (e.g. 2-amino-2-deoxy-D-glucose chitosamine)
have similar uptake characteristics (32) and may therefore
produce similar contrast patterns. Also, further glucosamine
oleﬁnic derivatives and ester derivatives on the glucose
ring show similar uptake and cellular internalization
properties, and may produce similar contrast patterns (33). It
is therefore highly likely that [U-13C6, 2 H7]glucose is taken up
into cells by transport systems similar to those used for FDG
uptake.
In conclusion, the ﬁrst nonradioactive images of glucose
distribution were obtained in live rats by hyperpolarized
MRI. The utility of this imaging approach in catheter angiography
was demonstrated by imaging during bolus injection, whereby
glucose was utilized as a safe, high-intensity, injectable
agent. Hyperpolarized [13C6, 2 H7]glucose MRI may offer radiation
free visualization of glucose uptake in health and disease.
Further studies are needed to compare such studies with
FDG-PET.

4. EXPERIMENTAL
4.1.

Materials

13

[U- C6, 2 H7]glucose and [2 H7]glucose were obtained from
Cambridge Isotopes Laboratories (Andover, MA, USA). Trityl free
radical (OX063) was obtained from GE Healthcare, (London, UK).
ProHance was purchased from Bracco Diagnostics Inc. (USA).
4.2.

Spectrometers and Scanner

T1 analyses at thermal equilibrium

T1 measurements at thermal equilibrium of 13C nuclei in glucose
analogs in a variety of conditions (magnetic ﬁeld strength,
concentration, osmolarity) were performed at 37  C with the
standard inversion recovery pulse sequence. Heteronuclear
irradiation (proton or deuterium) was not applied. The data were
ﬁtted to equation (1):
h
i

I ¼ I0 1  Ae t=T1
(1)
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Curve ﬁtting was carried out using Matlab software (MathWorks
Inc., Natick, MA, USA).
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Animals

Male Sprague–Dawley rats weighing approximately 565  64 g
(n = 4) were acclimatized to the animal housing for a week prior
to the study. The rats were fed ad libitum. Anesthesia was
induced with 5% isoﬂurane and maintained with 1.5–2.5%
isoﬂurane. All studies were performed under a protocol
approved by the University of Western Ontario’s Animal Use
Subcommittee. Following hyperpolarized studies, rats were
sacriﬁced by isoﬂurane overdose and intravenous injection of
potassium chloride. Hyperpolarized media were injected via a
tail vein catheter pre-washed with heparinized saline.
4.5.

Hyperpolarization, Dissolution and Injection

A typical preparation for the hyperpolarization experiment is
described: [U-13C6, 2 H7]glucose (80 mg, 414 mmol) was mixed
with 100 ml of water containing OX063 14 mM and ProHance
0.7 mM. The contrast agent ProHance was added to the preparations as it was previously shown that the addition of a Gd complex to the solid-state preparation increases the polarization
level reached at 3.35 T (34). We have previously shown that, for
pyruvate polarization, ProHance is a favorable Gd complex
contrast agent because it increased signiﬁcantly the solid-state
polarization (about 40%) but had a very small T1 shortening
effect in solution (<10%) (35). The DNP sample was hyperpolarized in a dissolution DNP polarizer (Hypersense, Oxford Instruments, Abingdon, UK) at 1.4 K, 94.1 GHz and 50 mW as previously
described (15).
Dissolution was performed in 4 ml of dissolution medium
containing 98 mM sodium chloride in water and 100 mg l1 EDTA.
The amount of sodium chloride in the dissolution medium
was calculated to complement the glucose concentration to
300 mOsm. A volume of 2.5 ml of this hyperpolarized medium
was typically injected into the rat. The bolus injection to the tail
vein started typically 15–20 s following dissolution.
4.6.

T1 measurements at ultra high ﬁelds (7 and 11.8 T) were
carried out using Varian NMR spectrometers (Agilent, Santa
Clara CA, USA) located at Hadassah–Hebrew University
Medical Center in Jerusalem, Israel. T1 measurements at 4.7 T
were carried out on a Bruker spectrometer (Billerica MA, USA)
located at the Technion, Haifa, Israel. Hyperpolarized data
were recorded on a 3 T clinical scanner (Discovery MR750, GE
Healthcare, Waukesha WI, USA) located at the Robarts Research
Institute of the University of Western Ontario, London, Ontario,
Canada.
4.3.

4.4.

Monitoring of Physiological Parameters

During the injection, an increase in heart beat rate and a
decrease in breathing rate were observed and resolved within
<1 min. These physiological changes were attributed to the
injection of large volume in a short time rather than to the
active ingredient in the hyperpolarized media (in the current
study, glucose). The rat was warmed to 36–37  C using a water
circulation bath. The body temperature was not continuously
monitored.
4.7.

MR Imaging and Spectroscopy

MRI was performed in the 3 T clinical MRI scanner (Discovery
MR750) equipped with a transmit/receive birdcage 13C RF coil,
10 cm i.d. (Morris Instruments, Ottawa, Ontario, Canada) and a
custom-built 1 H surface coil that ﬁtted within the 13C coil. The
animal was placed in a supine position at the center of the 13C
coil and the proton coil was centered underneath the animal’s
abdomen.
4.8.

In vivo Hyperpolarized 13C Imaging

Coronal projection 13C imaging was performed using a variable
ﬂip angle (36) gradient echo sequence with the following acquisition parameters: acquisition time 1 s, repetition time 17.7 ms,
echo time 8.9 ms, readout bandwidth 42 kHz, centric phase
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encoding, matrix size 64  64, and a ﬁeld-of-view 200  200 mm.
[U-13C6, 2 H7]glucose was injected as a 12 s bolus (2.5 ml) in each
experiment. Images were acquired between 8 and 20 s after the
start of the bolus injection. The dose of [U-13C6, 2 H7]glucose
injected was approximately 88 mg kg1 in each injection
(50 mg per 565 g).
4.9.

Determination of Polarization Level

For determination of polarization level in solution, we used
the same solid-state polarization and dissolution protocols that
were used in the in vivo studies. Within ca. 1 h, the polarization
in solid state prior to dissolution reached 83  3% (n = 3) of
the maximal solid-state polarization level, as calculated by
ﬁtting the polarization build-up curve. The enhancement
factor and corresponding polarization level in solution at 3 T
were measured 15  2 s (n = 3) from the moment of obtaining
the dissolved hyperpolarized media from the polarizer. This
delay was the time required for transport of the hyperpolarized
solution from the polarizer to the RF coil inside the MRI
system. A series of 128 excitations with a ﬂip angle of 10
and a repetition time of 3.5 s was acquired immediately upon
placement of the hyperpolarized media (3.5 ml in a syringe) in
the MRI RF coil. The hyperpolarized solution was warmed to
approximately 37  C when dispensed from the polarizer,
while the polarization measurements were made at room
temperature (about 20  C), so the sample probably
cooled somewhat during the transfer and measurement
time. The ﬁrst spectrum recorded in the magnet was compared
with a thermal equilibrium signal of a more concentrated
solution (520 mM in 5.6 ml of deionized water, containing 70 ml
of ProHance, which consists of 0.5 M Gd complex). The 13C signal
of the polarized [U-13C6, 2 H7]glucose media (26 mM in 314 mOsm
NaCl, as above) was too low to be detected at thermal
equilibrium. For this reason the hyperpolarized signal was
compared with a thermal equilibrium signal of the more
concentrated sample (520 mM) that was thermally equilibrated
to room temperature. The thermal equilibrium spectrum was
acquired with a ﬂip angle of 90 , repetition time of 3.5 s and
1024 excitations. The effect of differences in the number of
excitations, ﬂip angle and the amount of [U-13C6, 2 H7]glucose
was taken into account in the calculation of enhancement
factors and the corresponding polarization levels.
4.10.

Determination of T1 for [U-13C6, 2 H7]glucose at 3 T
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T1 measurements in a hyperpolarized state consisted of
recording the decay curve of the hyperpolarized signal
(acquired as described above, [U-13C6, 2 H7]glucose, 26 mM in
314 mOsm NaCl). The intensity data were analyzed using the
standard decay equation, where the effect of RF pulsation
(10 ) on the decay rate was taken into account using a
point-by-point correction of the data by a factor of 1/cos
(10 ). This correction factor for T1 measurement at hyperpolarized state is based on a theory developed by Day et al. in 2007
(37), following the initial work by Look and Locker in 1970 (38).
The correction factor of 1/cos(10 ) was applied to each data
point on the decay curve individually rather than as a cumulative correction of 1/cosn(10 ), where n would be the number
of pulses applied to the sample until that point. Curve ﬁtting
was carried out using Matlab software (The MathWorks Inc.,
Natick, MA, USA).
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